Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked

by Niravath, Polly, Eble, Tanya, Contreras, Alejandro, Li, Marilyn, Franco, Luis M, Rimawi, Mothaffar
Published in Exp Hematol Oncol (2015)

Towards personalized treatment for early stage HER2-positive breast cancer

by Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published in Nat Rev Clin Oncol (2019)

A Phase II Trial of Capecitabine Concomitantly With Whole-Brain Radiotherapy Followed by Capecitabine and Sunitinib for Brain Metastases From Breast Cancer

by Niravath, Polly, Tham, Yee Lu, Wang, Tao, Rodriguez, Angel, Foreman, Claudette, Hilsenbeck, Susan G., Elledge, Richard, Rimawi, Mothaffar
Published in Oncologist (2015)

EGFR Expression in Breast Cancer Association with biologic phenotype and clinical outcomes

by Rimawi, Mothaffar F., Shetty, Priya B., Weiss, Heidi L., Schiff, Rachel, Osborne, C. Kent, Chamness, Gary C., Elledge, Richard M.
Published 2010

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

by Veeraraghavan, Jamunarani, De Angelis, Carmine, Reis-Filho, Jorge S., Prat, Aleix, Rimawi, Mothaffar F., Pascual, Tomás, Osborne, C. Kent, Schiff, Rachel
Published in Breast (2017)

THERAPEUTIC POTENTIAL OF THE DUAL EGFR/HER2 INHIBITOR AZD8931 IN CIRCUMVENTING ENDOCRINE RESISTANCE

by Morrison, Gladys, Fu, Xiaoyong, Shea, Marty, Nanda, Sarmistha, Giuliano, Mario, Wang, Tao, Klinowska, Teresa, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel
Published 2014

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implication...

by Lu, Dan, Girish, Sandhya, Gao, Yuying, Wang, Bei, Yi, Joo-Hee, Guardino, Ellie, Samant, Meghna, Cobleigh, Melody, Rimawi, Mothaffar, Conte, Pierfranco, Jin, Jin Yan
Published 2014

Lumpectomy followed by radiation improves survival in HER2 positive and triple‐negative breast cancer with high tumor‐infiltrating lymphocytes compared to mastectomy alone

by Mouabbi, Jason A., Chand, Momal, Asghar, Ishaq A., Sakhi, Ramen, Ockner, Daniel, Dul, Carrie L., Hadid, Tarik, Aref, Amr, Rimawi, Mothaffar F., Hoyos, Valentina
Published in Cancer Med (2021)

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

by Huang, Catherine, Park, Catherine C, Hilsenbeck, Susan G, Ward, Robin, Rimawi, Mothaffar F, Wang, Yen-chao, Shou, Jiang, Bissell, Mina J, Osborne, C Kent, Schiff, Rachel
Published 2011

A phase II neoadjuvant trial of anastrozole, fulvestrant and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

by Massarweh, Suleiman, Tham, Yee L, Huang, Jian, Sexton, Krystal, Weiss, Heidi, Tsimelzon, Anna, Bayer, Amanda, Rimawi, Mothaffar, Cai, Wei Yen, Hilsenbeck, Susan, Fuqua, Suzanne, Elledge, Richard
Published in Breast Cancer Res Treat (2011)

Upregulation of Mucin4 in ER-positive/HER2-Overexpressing Breast Cancer Xenografts with Acquired Resistance to Endocrine and HER2-Targeted Therapies

by Chen, Albert C., Migliaccio, Ilenia, Rimawi, Mothaffar, Lopez-Tarruella, Sara, Creighton, Chad J., Massarweh, Suleiman, Huang, Catherine, Wang, Yen-Chao, Batra, Surinder K., Gutierrez, M. Carolina, Osborne, C. Kent, Schiff, Rachel
Published 2012

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER-2/neu Overexpressing Breast Tumor Xenografts

by Rimawi, Mothaffar F., Wiechmann, Lisa S., Wang, Yen-Chao, Huang, Catherine, Migliaccio, Ilenia, Wu, Meng-Fen, Gutierrez, Carolina, Hilsenbeck, Susan G., Arpino, Grazia, Massarweh, Suleiman, Ward, Robin, Soliz, Robert, Osborne, C. Kent, Schiff, Rachel
Published 2010

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy

by Litzenburger, Beate C., Creighton, Chad J., Tsimelzon, Anna, Chan, Bonita T., Hilsenbeck, Susan G., Wang, Tao, Carboni, Joan M., Gottardis, Marco M., Huang, Fei, Chang, Jenny C., Lewis, Michael T., Rimawi, Mothaffar F., Lee, Adrian V.
Published 2010

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexp...

by Rimawi, Mothaffar F., Mayer, Ingrid A., Forero, Andres, Nanda, Rita, Goetz, Matthew P., Rodriguez, Angel A., Pavlick, Anne C., Wang, Tao, Hilsenbeck, Susan G., Gutierrez, Carolina, Schiff, Rachel, Osborne, C. Kent, Chang, Jenny C.
Published 2013

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Lo...

by Dave, Bhuvanesh, Migliaccio, Ilenia, Gutierrez, M. Carolina, Wu, Meng-Fen, Chamness, Gary C., Wong, Helen, Narasanna, Archana, Chakrabarty, Anindita, Hilsenbeck, Susan G., Huang, Jian, Rimawi, Mothaffar, Schiff, Rachel, Arteaga, Carlos, Osborne, C. Kent, Chang, Jenny C.
Published 2011

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

by Wang, Yen-Chao, Morrison, Gladys, Gillihan, Ryan, Guo, Jun, Ward, Robin M, Fu, Xiaoyong, Botero, Maria F, Healy, Nuala A, Hilsenbeck, Susan G, Phillips, Gail Lewis, Chamness, Gary C, Rimawi, Mothaffar F, Osborne, C Kent, Schiff, Rachel
Published 2011

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and an...

by Ramirez, Arturo B., Bhat, Raksha, Sahay, Debashish, De Angelis, Carmine, Thangavel, Hariprasad, Hedayatpour, Sina, Dobrolecki, Lacey E., Nardone, Agostina, Giuliano, Mario, Nagi, Chandandeep, Rimawi, Mothaffar, Osborne, C. Kent, Lewis, Michael T., Stilwell, Jackie L., Kaldjian, Eric P., Schiff, Rachel, Trivedi, Meghana V.
Published in BMC Cancer (2019)

Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27

by Niravath, Polly, Chen, Bingshu, Chapman, Judy-Anne W., Agarwal, Sandeep K., Welschhans, Robert L., Bongartz, Tim, Kalari, Krishna R., Shepherd, Lois E., Bartlett, John, Pritchard, Kathleen, Gelmon, Karen, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Goss, Paul E., Ingle, James N.
Published in Clin Breast Cancer (2017)

Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor-Negative Breast Cancer

by Crew, Katherine D., Brown, Powel, Greenlee, Heather, Bevers, Therese B., Arun, Banu, Hudis, Clifford, McArthur, Heather L., Chang, Jenny, Rimawi, Mothaffar, Vornik, Lana, Cornelison, Terri L., Wang, Antai, Hibshoosh, Hanina, Ahmed, Aqeel, Terry, Mary Beth, Santella, Regina M., Lippman, Scott M., Hershman, Dawn L.
Published 2012

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

by Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel
Published in Br J Cancer (2018)